Dr Lalchandani Labs Ltd Share Price & Stock Analysis

Dr Lalchandani Labs Ltd (BSE: 541299) is a New Delhi, Delhi-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹6 Cr, it ranks #4,975 by market cap among the 6,197 Indian listed companies on FinBizNet, and #15 of 18 in Medical Diagnostic Centres. At ₹6.19 (as of 16 Nov 2026), the share price is 73.9% below its 52-week high of ₹23.69 and 6.5% above its 52-week low of ₹5.81. The share price is down 73.7% over one year and down 1.9% over three months.

Key Metrics

Current Price₹6.19
Market Cap₹6 Cr
BSE Code541299
SectorHealth Care > Health Care Equipment and Services > Health Care Providers and Services
Sub-IndustryHealth Care Services > Medical Diagnostic Centres
P/E Ratio92.4
Return on Equity4.28%
Return on Assets-1.86%
52-Week Range₹5.81 – ₹23.69
1-Year Price Change-73.7%
3-Month Price Change-1.9%
Beta (1Y)-0.55
HeadquartersNew Delhi, Delhi
Websitewww.lalchandanipathlab.com

Shareholding and Delivery

Delivery averaged 78.3% of traded volume across 12 BSE sessions (21 Oct 2026 – 13 Nov 2026).

About Dr Lalchandani Labs Ltd

Dr Lalchandani Labs Limited provides diagnostic and related healthcare tests and services in India. The company offers doctor consultation, pathology, radiology, hospital lab management, corporate health checkup, and blood bank services, as well as X-ray, TMT, ultrasound, 2D-echo, and medical fitness examinations. It also offers its products online. The company serves individual patients, hospitals and other healthcare providers, and corporate customers. Dr Lalchandani Labs Limited was founded in 1986 and is based in New Delhi, India.

Products and Services

1. B2B-This segment provides a range of diagnostic and related healthcare tests and services for use in core testing and patient diagnosis, as well as the prevention, monitoring, and treatment of disease and other health conditions. 2. B2C-This segment provides a range of diagnostic and related healthcare tests and services for use in core testing and patient diagnosis, as well as the prevention, monitoring, and treatment of disease and other health conditions. 3. Healthcare and Diagonis Services-This segment provides diagnostic and related healthcare tests and services. It offers patients and healthcare providers a range of diagnostic and related healthcare tests and services for use in core testing and patient diagnosis, as well as the prevention, monitoring, and treatment of disease and

Dr Lalchandani Labs Ltd vs Peers — Medical Diagnostic Centres

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Dr. Lal Pathlabs Ltd₹33,934 Cr66.421.48%₹874 Cr+28.7%
Vijaya Diagnostic Centre Limited₹14,665 Cr84.319.70%₹255 Cr+38.5%
Metropolis Healthcare Limited₹11,952 Cr61.513.37%₹497 Cr+14.9%
Throcare Technologies Ltd₹7,764 Cr47.628.74%₹271 Cr+7.5%
SURAKSHA DIAGNOSTIC LIMITED₹1,856 Cr55.413.84%₹99 Cr+6.9%
Krsnaa Diagnostics Ltd₹1,625 Cr16.810.89%₹271 Cr-27.0%
Gaudium IVF and Women Health Limited₹803 Cr27.416.08%₹37 Cr—
Chandan Healthcare Limited₹582 Cr21.918.43%₹81 Cr—
Dr Lalchandani Labs Ltd₹6 Cr92.44.28%—-73.7%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Dr Lalchandani Labs Ltd?

Dr Lalchandani Labs Ltd is trading at ₹6.19, with a market capitalisation of ₹6 Cr.

Which sector does Dr Lalchandani Labs Ltd belong to?

Dr Lalchandani Labs Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).

What are the key financial ratios of Dr Lalchandani Labs Ltd?

Dr Lalchandani Labs Ltd has a P/E of 92.4 and a return on equity of 4.28%.

What is the stock symbol of Dr Lalchandani Labs Ltd?

Dr Lalchandani Labs Ltd is listed on the BSE under the scrip code 541299.

How has Dr Lalchandani Labs Ltd's share price moved over the past year?

Dr Lalchandani Labs Ltd's share price is down 73.7% over one year and down 1.9% over three months. Its 52-week range is ₹5.81 to ₹23.69.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.